MedTrace Logo

Usefullness of Peri-operative Tranexamic Acid in Primary Breast Augmentation With Implants.

NCT03364569 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-07-29

No results posted yet for this study

Summary

Tranexamic acid (TXA), as an antifibrinolytic agent, has shown a tremendous interest in surgery by reducing blood loss ; but only few articles have been reported in the plastic surgery scope. The aim of this study was to investigate whether oral administration of TXA reduces surgical drainage in primary breast augmentation using implants.

Conditions

  • Plastic Surgery

Interventions

PROCEDURE

Tranexamic acid

Participants with taking tranexamic acid (2 x 1g per day) as a preventive and without adjuvant treatment.

Sponsors & Collaborators

  • Hôpital NOVO

    lead OTHER

Principal Investigators

  • Thomas COLSON · Hôpital NOVO

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-01
Primary Completion
2016-04-01
Completion
2016-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03364569 on ClinicalTrials.gov